Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer - Related Studies

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

This study is ongoing, but not recruiting participants.

Study NCT00005049. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Colorectal Cancer
		Gastric Cancer
		Gastrointestinal Carcinoid Tumor
		Gastrointestinal Stromal Tumor
		Ovarian Cancer
		Peritoneal Cavity Cancer
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Carcinoid Tumor
		Colorectal Neoplasms
		Duodenal Neoplasms
		Gastrointestinal Neoplasms
		Gastrointestinal Stromal Tumors
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms
		Malignant Carcinoid Syndrome
		Ovarian Neoplasms
		Stomach Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Adnexal Diseases
		Carcinoma
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Ileal Diseases
		Intestinal Diseases
		Jejunal Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Ovarian Diseases
		Rectal Diseases
		Stomach Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		carboplatin
		cisplatin
		floxuridine

5	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		New York University School of Medicine
		National Cancer Institute (NCI)